Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet

MarketWire Canada January 4, 2017

IntelGenx Announces Development and Commercialization Agreement with Endo Ventures

MarketWire Canada December 27, 2016

RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT® for Migraines with Pharmatronic Co. in South Korea

GlobeNewswire December 14, 2016

IntelGenx and RedHill Biopharma Announce Definitive Agreement for Commercialization of RIZAPORT(R) for Migraines with Pharmatronic Co. in South Korea

MarketWire Canada December 14, 2016

IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional Product

MarketWire Canada December 1, 2016

IntelGenx Secures a License For Tadalafil Erectile Dysfunction Dosing Patent

MarketWire Canada November 21, 2016

IntelGenx Reports Profitable Third Quarter with Increased Growth in Revenues from Second Quarter

MarketWire Canada November 10, 2016

IntelGenx to Report Third Quarter 2016 Financial Results on November 10, 2016

MarketWire Canada November 1, 2016

IntelGenx and RedHill Biopharma Announce RIZAPORT(R) Commercialization Term Sheet with Pharmatronic Co. for Korea

MarketWire Canada September 21, 2016

RedHill Biopharma and IntelGenx Announce RIZAPORT® Commercialization Term Sheet with Pharmatronic Co. for Korea

GlobeNewswire September 21, 2016

IntelGenx Grants Stock Options

MarketWire Canada September 16, 2016

IntelGenx Announces Development and Commercialization Agreement for Three Products with Chemo Group, A Global Pharmaceutical Company

MarketWire Canada September 12, 2016

IntelGenx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and the 11th Annual Singular Research Conference

MarketWire Canada September 7, 2016

IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain

MarketWire Canada August 22, 2016

VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review

MarketWire Canada August 22, 2016

IntelGenx Reports Second Quarter 2016 Financial Results and Appointment of New Director

MarketWire Canada August 11, 2016

IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million

MarketWire Canada August 5, 2016

IntelGenx to Report Second Quarter 2016 Financial Results on August 11, 2016

MarketWire Canada August 2, 2016

IntelGenx to Initiate Phase 1 Trial of Montelukast

MarketWire Canada July 13, 2016

IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction

MarketWire Canada July 11, 2016